RLD2302 + RLD2102

RLD2302 + RLD2102 is a combination of two investigational agents referenced in early phase clinical trials conducted primarily by Hanmi Pharmaceutical. These agents are being studied together for pharmacokinetic characteristics, safety, and potential drug-drug interactions in healthy subjects. Publicly available information does not specify the precise chemical identities, mechanisms of action, or intended primary indications for RLD2302 or RLD2102, as these appear to be in the early clinical development phase and details remain undisclosed by the sponsor. Their developmental context suggests they could be components of fixed-dose combination products also studied with reference to Hanmi pipeline drugs such as HCP2303 and HCP1306[1][3][5][7][8].